Skip to main content
spacbrain

AEON Biopharma

Closed (deSPAC)

Health Care · clinical-stage biopharmaceutical company

What it is
Biopharma AEON is a clinical stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets
What it’s doing now
Merging with Priveterra Acquisition Corp. (AEON) — closed (despac).
What you should know
The deal carries a $40M minimum-cash condition — heavy redemptions can break it.

The business, per its filings

SEC primary

Biopharma AEON is a clinical stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. The Company is dedicated to innovation in the rapidly expanding therapeutic botulinum toxin market and believes its therapeutic-only focus will allow AEON to advance safe and effective treatment options to patients, while delivering differentiated economics to payors and physicians. The Company continues to evaluate additional therapeutic indications for development based on a comprehensive product assessment process designed to identify those indications where it believes ABP-450 can attain clinical, regulatory, and commercial success. More information about AEON can be found at www.aeonbiopharma.com .

Source: S-4/A, accession 0001104659-23-053372

What the company says about itself

Web research — not audited

AEON Biopharma is dedicated to advancing access to therapeutic botulinum toxins through biosimilarity. The company is developing ABP-450 (prabotulinumtoxinA) as a branded biosimilar to BOTOX®, aiming to broaden treatment access for neuromuscular conditions by leveraging the FDA’s biosimilar pathway and an established manufacturing platform.

Markets:
biopharmaceuticals | therapeutic botulinum toxin
Products:
ABP-450 (prabotulinumtoxinA)
What our web check found

[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Aggregate gross proceeds to the Company are expected to be approximately $20.0 million." [https://investors.aeonbiopharma.com/static-files/f8b562ad-0c13-4f5c-a52a-864e27c48db3]

Source: https://aeonbiopharma.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

AEON Biopharma is merging with Priveterra Acquisition Corp. (AEON) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $7M · unsourced
Minimum cash to close$40M

Structure per SEC accession(s) 0001104659-23-076531, 0001104659-23-053372. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is AEON Biopharma going public?

AEON Biopharma has an approved merger with the SPAC Priveterra Acquisition Corp. (AEON). Deal status: Closed (deSPAC).

Does AEON Biopharma have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals